Skip to main
GRDN
GRDN logo

GRDN Stock Forecast & Price Target

GRDN Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardian Pharmacy Services Inc. is positioned for a positive financial outlook due to its strong technological capabilities, which are anticipated to enhance conversations around value-based care and improve operational efficiency through the integration of its tech platforms within newly acquired operations. The company benefits from significant market share among its pharmacies, coupled with a robust tech stack, creating attractive differentiators that support earnings potential, especially from recently acquired facilities. Furthermore, Guardian’s use of robotic dispensing technology significantly enhances operational efficiency, achieving improved accuracy and rapid fulfillment times, thereby further supporting its financial prospects.

Bears say

Guardian Pharmacy Services Inc. faces several significant risks that contribute to a negative outlook on its stock, primarily stemming from potential changes in regulation and reimbursement policies. Additionally, challenges related to supply chain disruptions and the difficulty in hiring or retaining qualified clinical staff may adversely impact the company's operational efficiency and service delivery. Moreover, the reliance on technology assets and the need to effectively manage relationships with long-term care facilities could hinder the company's ability to successfully integrate acquisitions and sustain growth.

GRDN has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardian Pharmacy Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardian Pharmacy Services Inc (GRDN) Forecast

Analysts have given GRDN a Buy based on their latest research and market trends.

According to 3 analysts, GRDN has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardian Pharmacy Services Inc (GRDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.